Court Allowed Amgen Lawsuit to Proceed
The First Circuit Court of Appeals ruled that a mother may pursue a liability claim against Amgen over her son's 2018 death.
Updated on Oct. 13, 2026 in Biotech
A federal appeals court has permitted a lawsuit against pharmaceutical company Amgen to move forward. The case involves a Massachusetts mother who is suing the company following the death of her 25-year-old son, who had taken the migraine medication Aimovig.
Why it matters
The ruling is significant because the First Circuit Court of Appeals established that the plaintiff may pursue a new theory of liability in the case. This decision impacts the legal standing of the litigation regarding the safety profile of the medication.
The lawsuit centers on the use of Aimovig, a drug that had been recently approved by regulators at the time the 25-year-old man took the medication in 2018. The court-sanctioned legal theory examines the liability of the manufacturer regarding the product.
The players
Amgen Inc.
This is a global biotechnology company that develops and manufactures human therapeutics, including the migraine medication Aimovig.
First Circuit Court of Appeals
This is a federal court that hears appeals from the district courts located within its jurisdiction, including the state of Massachusetts.
The details
The First Circuit Court of Appeals issued a ruling that allows the plaintiff to advance a specific legal theory against Amgen Inc. in connection to the death of her son. The litigation stems from a complaint filed by a Massachusetts mother after her son died following his use of the migraine treatment.
Timeline
The deceased man took the medication Aimovig in 2018.
The First Circuit Court of Appeals issued the ruling on October 13, 2026.
The Tech Race
This case mirrors historical legal challenges involving the post-market safety profiles of high-profile, recently approved pharmaceutical treatments. It highlights the evolving landscape for manufacturer liability as courts weigh regulatory approval against subsequent patient outcomes.
The court's decision allows for the continued pursuit of accountability, which may influence how patients and families view manufacturer disclosures and drug safety information. Residents in Massachusetts should monitor the case as it proceeds, as it may set precedents for pharmaceutical liability standards.
The takeaway
This ruling establishes that plaintiffs may advance new liability theories in pharmaceutical litigation. Patients should consult their medical providers regarding current safety warnings for any prescribed medications.
Further reading
For more context on the current regulatory and legal environment, visit Biotech.
